Education
About Us
Working with TipRanks
Follow Us
Innate Pharma (IPHA)
NASDAQ:IPHA
Earnings Data
Report Date
Sep 17, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: 0.55%
|Next Earnings Date:Sep 17, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant achievements in clinical trial progress, regulatory milestones, and financial stability. However, strategic shifts and decreased R&D expenses indicate some challenges in specific areas.Company Guidance
During the call, Innate Pharma provided various metrics reflecting its progress and future guidance. The company highlighted the advancement of their clinical programs, including IPH6501, with the first patients recruited into the Phase 1 trial in the first half of 2024. IPH4502, their Nectin-4 targeted ADC, dosed its first patients in January 2025 following IND clearance in September 2024. Lacutamab received FDA breakthrough therapy designation, with regulatory discussions for a confirmatory Phase 3 ongoing. Financially, Innate reported revenue of €20.1 million for 2024, with €12.6 million from collaboration agreements and a research tax credit of €7.5 million. Operating expenses were €71.7 million, with 73% allocated to R&D, and the company maintained cash and equivalents of €91.1 million as of December 31, 2024, sufficient to fund operations through mid-2026.IPH65 Phase 1 Trial Progress
The first patients were recruited into the Phase 1 dose finding trial for IPH65, a key focus for Innate, marking a critical step in the product's clinical development.
FDA Breakthrough Therapy Designation for Lacutamab
Lacutamab received breakthrough therapy designation from the FDA, bringing it closer to potential accelerated approval based on strong data.
Strong Pipeline and Strategic Focus
Innate Pharma continues to advance a robust pipeline with eight innovative assets currently in the clinic, emphasizing NK cell engagers, antibody-drug conjugates, and late-stage assets.
Financial Stability
Cash, cash equivalents, short-term investments, and financial assets amounted to EUR91.1 million as of December 31, 2024, with sufficient cash to fund operations through mid-2026.
---
IPHA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IPHA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.81 | $1.97 | +8.84% |
| Sep 12, 2024 | $2.36 | $2.28 | -3.39% |
| Mar 21, 2024 | $2.50 | $2.41 | -3.60% |
| Sep 14, 2023 | $3.06 | $3.07 | +0.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Innate Pharma (IPHA) report earnings?
Innate Pharma (IPHA) is schdueled to report earning on Sep 17, 2025, TBA Not Confirmed.
What is Innate Pharma (IPHA) earnings time?
Innate Pharma (IPHA) earnings time is at Sep 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPHA EPS forecast?
IPHA EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.
---